Inositol induces mesenchymal-epithelial reversion in breast cancer cells through cytoskeleton rearrangement

Experimental Cell Research

Volumn 345, Issue 1, 2016, Pages 37-50

  Dinicola, Simona ^a   Fabrizi, Gianmarco ^a   Masiello, Maria Grazia ^a   Proietti, Sara ^a   Palombo, Alessandro ^a   Minini, Mirko ^a   Harrath, Abdel Halim ^b   Alwasel, Saleh H ^b   Ricci, Giulia ^c   Catizone, Angela ^a   Cucina, Alessandra ^a,d   Bizzarri, Mariano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d POLICLINICO UMBERTO I   (Italy)

Author keywords

Cytoskeleton; EMT; Inositol; Invasion; MET; Motility

Indexed keywords

BETA CATENIN; COFILIN; CYCLOOXYGENASE 2; F ACTIN; FASCIN; GAMMA SECRETASE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL; NERVE CELL ADHESION MOLECULE; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PRESENILIN 1; PROTEIN; PROTEIN KINASE B; PROTEIN SNAI1; RHO KINASE; RHO KINASE 1; RHO KINASE 2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ACTIN BINDING PROTEIN; CADHERIN; CARRIER PROTEIN; FSCN1 PROTEIN, HUMAN; SECRETASE;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; CELL MOTILITY; CELL SHAPE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOSKELETON; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FILOPODIUM; HUMAN; HUMAN CELL; LAMELLIPODIUM; MESENCHYMAL EPITHELIAL REVERSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; BREAST TUMOR; CELL MOTION; DRUG EFFECTS; EPITHELIUM CELL; FEMALE; IMMUNOBLOTTING; MESODERM; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR INVASION; WOUND HEALING;

AMYLOID PRECURSOR PROTEIN SECRETASES; BETA CATENIN; BREAST NEOPLASMS; CADHERINS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETON; DOWN-REGULATION; ENZYME ACTIVATION; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOBLOTTING; INOSITOL; MESODERM; MICROFILAMENT PROTEINS; NEOPLASM INVASIVENESS; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PRESENILIN-1; PROTO-ONCOGENE PROTEINS C-AKT; RHO-ASSOCIATED KINASES; VIMENTIN; WOUND HEALING;

EID: 84973879574     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2016.05.007     Document Type: Article

References (51)

1. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 2003, 15:740-746.
2. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
3. Hiscox S., Morgan L., Barrow D., Dutkowskil C., Wakeling A., Nicholson R.I. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin. Exp. Metastasis 2004, 21:201-212.
4. Kurrey N.K., Jalgaonkar S.P., Joglekar A.V., Ghanate A.D., Chaskar P.D., Doiphode R.Y., Bapat S.A. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009, 27:2059-2068.
5. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7:131-142.
6. Yao D., Dai C., Peng S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol. Cancer Res. 2011, 9:1608-1620.
7. Acloque H., Adams M.S., Fishwick K., Bronner-Fraser M., Nieto M.A. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Investig. 2009, 119:1438-1449.
8. Ginnebaugh K.R., Ahmad A., Sarkar F.H. The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer. Expert Opin. Ther. Target 2014, 18:731-745.
9. Downes C.P. The cellular function of myo-inositol. Biochem. Soc. Trans. 1989, 17:259-268.
10. Kane M.T., Norris M., Harrison P.A. Uptake and incorporation of inositol by preimplantation mouse embryos. J. Reprod. Fertil. 1992, 96:617-625.
11. Larner J. D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance. Int. J. Exp. Diabetes Res. 2002, 3:47-60.
12. Dinicola S., Chiu T.T., Unfer V., Carlomagno G., Bizzarri M. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. J. Clin. Pharmacol. 2014, 54:1079-1092.
13. Vucenik I., Shamsuddin A.M. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J. Nutr. 2003, 133(Suppl 1):3778S-3784S.
14. Huang C., Liang N.C. Increase in cytoskeletal actin induced by inositol 1,4-bisphosphate in saponin-permeated pig platelets. Cell Biol. Int. 1994, 18:797-804.
15. Suzuki T., Hara H. Phytate hydrolysate induces circumferential F-actin ring formation at cell-cell contacts by a Rho-associated kinase dependent mechanism in colorectal cancer HT-29 cells. Mol. Nutr. Food Res. 2010, 54:1807-1818.
16. Ferranti F., Caruso M., Cammarota M., Masiello M.G., Corano Scheri K., Fabrizi C., Fumagalli L., Schiraldi C., Cucina A., Catizone A., Ricci G. Cytoskeleton modifications and autophagy induction in TCam-2 seminoma cells exposed to simulated microgravity. Biomed. Res. Int. 2014, 2014:904396.
17. Pasqualato A., Lei V., Cucina A., Dinicola S., D'Anselmi F., Proietti S., Masiello M.G., Palombo A., Bizzarri M. Shape in migration: quantitative image analysis of migrating chemoresistant HCT-8 colon cancer cells. Cell Adhes. Migr. 2013, 7:450-459.
18. Weichsel J., Herold N., Lehmann M.J., Kräusslich H.G., Schwarz U.S. A quantitative measure for alterations in the actin cytoskeleton investigated with automated high-throughput microscopy. Cytometry A 2010, 77:52-63.
19. Z. Püspöki, M. Storath, D. Sage, M. Unser, Transforms and Operators for Directional bioimage Analysis: A Survey, . http://https://pdfs.semanticscholar.org/78e2/6c10a0316db7a9f0a90f3bd8823665090a1d.pdf.
20. Gustafson A.M., Soldi R., Anderlind C., Scholand M.B., Qian J., Zhang X., Cooper K., Walker D., McWilliams A., Liu G., Szabo E., Brody J., Massion P.P., Lenburg M.E., Lam S., Bild A.H., Spira A. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci. Transl. Med. 2010, 2:26ra25.
21. Woodgett J.R. Recent advances in the protein kinase B signaling pathway. Curr. Opin. Cell Biol. 2005, 17:150-157.
22. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004, 30:193-204.
23. Lim J., Kim J.H., Paeng J.Y., Kim M.J., Hong S.D., Lee J.I., Hong S.P. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J. Clin. Pathol. 2005, 58:1199-1205.
24. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4:988-1004.
25. Han W., Gills J.J., Memmott R.M., Lam S., Dennis P.A. The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prev. Res. 2009, 2:370-376.
26. Grille S.J., Bellacosa A., Upson J., Klein-Szanto A.J., van Roy F., Lee-Kwon W., Donowitz M., Tsichlis P.N., Larue L. The protein kinase Akt induces epithelial-mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003, 63:2172-2178.
27. Peinado H., Portillo F., Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int. J. Dev. Biol. 2004, 48:365-375.
28. Orsulic S., Huber O., Aberle H., Arnold S., Kemler R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1- mediated transactivation. J. Cell Sci. 1999, 112:1237-1245.
29. Medici D., Hay E.D., Olsen B.R. Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol. Biol. Cell 2008, 19:4875-4887.
30. Graff J.R., Herman J.G., Lapidus R.G., Chopra H., Xu R., Jarrard D.F., Isaacs W.B., Pitha P.M., Davidson N.E., Baylin S.B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995, 55:5195-5199.
31. Serini G., Bochaton-Piallat M.L., Ropraz P., Geinoz A., Borsi L., Zardi L., Gabbiani G. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-1. J. Cell. Biol. 1998, 142:873-881.
32. Fortini M.E. Gamma-secretase-mediated proteolysis in cell-surface-receptor signaling. Nat. Rev. Mol. Cell Biol. 2002, 3:673-684.
33. Han J., Shen Q. Targeting γ-secretase in breast cancer. Breast Cancer Target Ther. 2012, 4:83-90.
34. Le Clainche C., Carlier M.F. Regulation of actin assembly associated with protrusion and adhesion in cell migration. Physiol. Rev. 2008, 88:489-513.
35. Xie J.J., Xu L.Y., Zhang H.H., Cai W.J., Mai R.Q., Xie Y.M., Yang Z.M., Niu Y.D., Shen Z.Y., Li E.M. Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells. Biochem. Biophys. Res. Commun. 2005, 337:355-362.
36. Hashimoto Y., Skacel M., Adams J.C. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?. Int. J. Biochem. Cell Biol. 2005, 37:1787-1804.
37. Lappalainen P., Drubin D.G. Cofilin promotes rapid actin filament turnover in vivo. Nature 1997, 388:78-82.
38. Carlier M.F., Laurent V., Santolini J., Melki R., Didry D., Xia G.X., Hong Y., Chua N.H., Pantaloni D. Actin depolymerizing factor (ADF/cofilin) enhances the rate of filament turnover: implication in actin-based motility. J. Cell Biol. 1997, 136:1307-1322.
39. Gilkes D.M., Xiang L., Lee S.J., Chaturvedi P., Hubbi M.E., Wirtz D., Semenza G.L. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancercells. Proc. Natl. Acad. Sci. USA 2014, 111:E384-E393.
40. Wyckoff J.B., Pinner S.E., Gschmeissner S., Condeelis J.S., Sahai E. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr. Biol. 2006, 16:1515-1523.
41. Liu S., Goldstein R.H., Scepansky E.M., Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res. 2009, 69:8742-8751.
42. Itoh K., Yoshioka K., Akedo H., Uehata M., Ishizaki T., Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 1999, 5:221-225.
43. Horwitz A.R., Parsons J.T. Cell migration: movin' on. Science 1999, 286:1102-1103.
44. Michell R.H. Inositol derivatives: evolution and functions. Nat. Rev. Mol. Cell Biol. 2008, 9:151-161.
45. Chen W., Deng Z., Chen K., Dou D., Song F., Li L., Xi Z. Synthesis and in vitro anticancer activity evaluation of novel bioreversible phosphate inositol derivatives. Eur. J. Med. Chem. 2015, 93:172-181.
46. Shamsuddin A.K.M., Vucenik I. IP6 and inositol in cancer prevention and therapy. Curr. Cancer Ther. Rev. 2005, 1:259-269.
47. Bacić I., Druzijanić N., Karlo R., Skifić I., Jagić S. Efficacy of IP6+ inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study. J. Exp. Clin. Cancer Res. 2010, 29:12.
48. Chao Y.L., Shepard C.R., Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol. Cancer 2010, 9:179.
49. Eger A., Mikulits W. Models of epithelial-mesenchymal transition. Drug Discov. Today Dis. Model 2005, 2:57-63.
50. Grünert S., Jechlinger M., Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol. 2003, 4:657-665.
51. Holub B.J. Nutritional, biochemical, and clinical aspects of inositol and phosphatidylinositol metabolism. Can. J. Physiol. Pharmacol. 1984, 62:1-8.